Abstract
Objectives
The present study aimed to investigate the expression level of MicroRNA-25 (miR-25) in epithelial ovarian cancer (EOC) tissue, and examine its relationship with clinicopathological factors and prognosis of patients with EOC.
Methods
Expression levels of miR-25 in 86 pairs of EOC tissue and adjacent normal tissue were measured by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). The comparison of the expression level of miR-25 between EOC tissue and adjacent normal tissue was performed using the two-sample Student’s t test. The correlation between the expression of miR-25 and clinicopathological characters was assessed with the two-sample Student’s t test. The overall survival was analyzed by log-rank test, and survival curves were plotted according to Kaplan–Meier.
Results
The expression level of miR-25 in EOC tissue was significantly higher than in adjacent normal tissue. The miR-25 expression level was significantly positively correlated with tumor stage, histology, and regional lymph node involvement (P < 0.05). Kaplan–Meier analysis showed that patients with higher levels of miR-25 had significantly poorer survival than those with lower expression of this miRNA in patients, with a 6-year overall survival of 15.96 and 45.89 %, respectively, (P = 0.001). In the multivariate Cox proportional hazards analysis, high miR-25 expression was independently associated with poor survival (P = 0.002; HR = 2.119; 95 % CI = 1.568–3.221).
Conclusion
The increased expression of miR-25 is closely related to poor prognosis of EOC, indicating that miR-25 may serve as a predictive biomarker for the prognosis of EOC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, et al. Molecular genetics and epidemiology of epithelial ovarian cancer (review). Oncol Rep. 2011;26(6):1347–56.
Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl 3:274–81.
Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;130(3):674–81.
Xu L, Cai J, Yang Q, Ding H, Wu L, Li T, et al. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol. 2013;139(8):1257–77.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
Cho WC. MicroRNAs in cancer—from research to therapy. Biochim Biophys Acta. 2010;1805(2):209–17.
Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001;107(7):823–6.
Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.
Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008;68(20):8191–4.
Savita U, Karunagaran D. MicroRNA-106b-25 cluster targets beta-TRCP2, increases the expression of Snail and enhances cell migration and invasion in H1299 (non small cell lung cancer) cells. Biochem Biophys Res Commun. 2013;434(4):841–7.
Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 2009;37(5):1672–81.
Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG, et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 2009;100(7):1234–42.
Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3(117):ra29.
Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27(2):594–8.
Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013;93(1):98–104.
Spiliotis J, Halkia E, Roukos DH. Ovarian cancer screening and peritoneal carcinomatosis: standards, ‘omics’ and miRNAs for personalized management. Expert Rev Mol Diagn. 2011;11(5):465–7.
Kim BH, Hong SW, Kim A, Choi SH, Yoon SO. Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 2013;107(5):505–10.
Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett. 2013;335(1):168–74.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, X., Meng, X., Li, H. et al. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Transl Oncol 16, 954–958 (2014). https://doi.org/10.1007/s12094-014-1178-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-014-1178-6